{"changes":[{"companyHref":"/c/temperobio-com","date":"2026-09-25","documentUrl":null,"domain":"temperobio.com","fact":"latest round","name":"Tempero Bio, Inc.","new":{"amountUsd":76958457,"date":"2025-11-04","lead":null,"type":null},"old":{"amountUsd":76958457,"date":"2025-11-04","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-05-08","slug":"temperobio-com","status":"attributed","url":"https://whoraisedwhat.com/c/temperobio-com"}],"country":"US","description":"Tempero Bio is a clinical-stage biopharma developing TMP-301, an oral mGluR5 modulator, to treat substance use disorders like cocaine and alcohol addiction. It serves patients with addiction and their clinicians, advancing into Phase 2. Its edge is dampening rather than blocking glutamate signaling, validated by PET occupancy.","domain":"temperobio.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":37.804456,"lng":-122.271356,"location":"OAKLAND, CA","name":"Tempero Bio, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":76958457,"currency":"USD","date":"2025-11-04","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"temperobio-com","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"temperobio.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://temperobio.com"},{"fact":"description","publisher":"temperobio.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://temperobio.com"}],"stage":null,"techStack":["Google Cloud CDN","Sentry","Partytown","Vercel Speed Insights","WebsiteBuilder","Wix","Google Cloud","React","lodash ."],"totalRaisedUsd":76958457,"updatedAt":"2026-05-08"}